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Introduction
Health technology assessment (HTA) is now an established input
to health-care decision-making in many countries. For example,
the International Network of Agencies for Health Technology
Assessment (INAHTA) has members from 24 countries including
North and Latin America, Europe, Asia, Australia and New
Zealand, and provides a “forum for the identiﬁcation and pursuit
of interests common to health technology assessment agencies”
[1]. Organizations such as INAHTA have come about because
HTA is based upon a general set of principles and involves the
study of the medical, social, ethical, and economic implications
of the development, diffusion, and use of a health technology. In
this article, arguments are presented to illustrate that despite
these common principles, the process of HTA, and more particu-
larly its economic evaluation component, needs to take a
national approach toward evaluation. These arguments are not
against the learning of lessons from work conducted in other
jurisdictions, but rather that the differences between countries
means that the results of an economic evaluation conducted in
one setting might not be applicable to another and as a conse-
quence, country-speciﬁc evaluations are needed that reﬂect the
needs of the decision-makers in that country.
Generalizability andTransferability
It is argued by Simoens that the results of economic evaluation are
generalizable from one setting to another if, withoutmodiﬁcation,
they are believed to be applicable to that setting. For this to
happen, not only do the data inputs to the economic evaluation
have to be applicable but also the way in which they relate to each
other in the original setting has to be consistent with the way in
which they should be brought together in the new setting. Differ-
ences in the culture, organization of health care and other sectors
of the economy may all change the patterns of care between
settings and hence change the way in which costs and beneﬁts are
accrued. If patterns of care and other factors affecting the delivery
of health care are similar, it may be possible to repeat an analysis
using local data on costs, utilities, etc. This was an approach
adopted by Coyle et al. who adapted a UK model comparing the
cost-effectiveness ofminimally invasive total hip replacementwith
standard total hip replacement to a Canadian setting [2]. In this
analysis, Canadian data on costs and utilities were substituted for
UK data. Underlying data on the epidemiology/natural history of
people after total hip replacement and on the relative effectiveness
of the two procedures were assumed to be same as that used in the
UK model. Such an approach was thought acceptable as the
underlying patterns of carewere believed to be similar between the
two countries. In this particular situation, the policy conclusion
with respect to the use of minimally invasive total hip replacement
was similar for both the UK and Canada—primarily because of
the absence of evidence on relative effectiveness. In other situa-
tions, it is possible that a different policy conclusion might be
drawn. For example, in an economic evaluation of the cost-
effectiveness of bisphosphonates to prevent hip fractures, it was
found that bisphosphonates were likely to be cost-effective in
Ottawa but not in Texas [3]. One of the reasons for this was that
the underlying risk of falling, and hence the risk of hip fractures,
was lower in Texas than in Ottawa. This meant that the capacity
to beneﬁt from bisphosphonates was much lower in Texas than in
Ottawa. What these examples illustrate is that, as Simoens argues,
it may be possible to make economic evaluations transferable
between settings.
In such a situation, international cooperation may be desir-
able and indeed the hip replacement example was completed
from start to ﬁnish with the express intention of conducting an
evaluation for both the UK and Canada.
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It may be possible to reﬁne the data inputs from an evaluation
conducted in one jurisdiction to make them applicable to
another. Nevertheless, although collaboration may be useful, it
has been argued that there are many reasons why the results of
single economic studies may not be transferable between differ-
ent places and times [4–6].
The Need to Reﬂect National
Decision-Making Requirements
One reason that can limit the transferability of economic evalu-
ations is that an economic evaluation conducted in one setting
may use methods that are deemed inappropriate for use in
another setting. This might be caused by variations between
analysts in terms of what makes an acceptable evaluation. It may
also reﬂect lack of standardization of methods; lack of compli-
ance with accepted methods of economic evaluation; and meth-
odological creep over time. International efforts to develop and
apply standards may help in this respect. Nevertheless, within
HTA an economic evaluation has to inform the judgements that
the national or local decision-maker has to make. In economic
terms, a decision-maker should consider the opportunity costs of
changing the patterns of care in his/her own jurisdiction. Never-
theless, each country has its own health-care systems with its
own particular pattern of resource use and its own particular set
of alternative uses for these resources. Therefore, the opportunity
cost of these resources will differ. The type of information that
each jurisdiction decides as necessary to inform decisions about
the allocation of resources also differs. A good example of this
can be drawn from the comparison of the way economic evalu-
ation is used to inform decisions in England and in Germany. In
England, the National Institute for Health and Clinical Excel-
lence (NICE) has tended to focus on the incremental cost per
quality-adjusted life-year (QALY) gained. It has adopted an
explicit threshold of £20,000 per QALY and recommends that a
common approach be taken to measure costs and beneﬁts across
therapeutic areas [7]. In contrast, in Germany the Institut Für
Qualität und Wirtschaftkeit im Gesundheitswesen (Institute for
Quality and Efﬁciency in Health Care, IQWiG) has focused on
the efﬁciency of resource use within a speciﬁc therapeutic area
and has advocated the use of an efﬁciency frontier to inform
decisions [8].
Methodological criticisms can be advanced for both
approaches. The use of a threshold value for a cost per QALY
does not inform a decision-maker about where the resources
required to implement a more effective intervention will come
from. It also requires a method of eliciting QALYs that can
capture the beneﬁts of all relevant health-care interventions. The
use of an efﬁciency frontier can be criticized because what inter-
ventions lie on the efﬁciency frontier will depend upon the
method used to measure beneﬁts. Therefore, choosing a different
measure of beneﬁt may change the shape of the efﬁciency frontier
in a given therapeutic area. Furthermore, without a common
method of measuring beneﬁts, it is difﬁcult to draw judgements
about efﬁcient allocation of resources across therapeutic areas.
The merits or otherwise of the approaches adopted within
individual jurisdictions can be debated and over time, if neces-
sary, reﬁned. Nevertheless, at any given point in time, those
analysts conducting economic evaluation for national decision-
makers such as NICE or IQWiG are expected to conduct them
using methods deemed relevant to that organization.
The Importance of Context
The IQWiG Technical Document on Modelling states that:
. . . data . . . are relevant to Germany, including not only
costs, but also clinical practice patterns, demographics and
epidemiology [9].
Therefore, when judging whether an economic evaluation can
be made applicable to Germany requires an understanding of the
context into which a new intervention might be introduced. How
an intervention will be adopted in a given setting, what service or
services it might displace, and how it might ﬁt into an overall
package of care may depend upon a range of factors including
providers’ personal and professional characteristics, patients’
physical and psychosocial characteristics, practice settings, and
organizational and structural features of health-care systems.
Hence, costs, effectiveness, and cost-effectiveness will vary.
An example of the effects of context can be seen by consid-
ering the hypothetical example of an economic evaluation com-
paring two different methods of surgical treatment for angle
closure glaucoma (a common cause of blindness). If the economic
evaluation were to be conducted for both the UK and Singapore,
then it is likely that the care pathways that patients would follow
in each country will differ. Speciﬁcally, care after successful and
unsuccessful initial treatment might differ because the beliefs of
practitioners about the value (and hence availability) of subse-
quent treatments might differ. Furthermore, differences in the
method of ﬁnancing health care may alter patients’ behavior. For
example, differences in out-of-pocket expenses may alter the use
of services after surgery, and hence alter both longer-term effec-
tiveness as well as costs. The implication of this is that the
structure of a model in terms of the sequence of therapies may
vary between countries.
The Need for Collaboration
Thus far, some arguments have been presented as to why eco-
nomic evaluation needs to take a national approach. It has been
argued that because of differences in terms of the decision-
making context and how this context affects the type of data
deemed relevant, the relationship between costs and beneﬁts, and
the values attached to costs and beneﬁts, the scope for general-
izing the results of an economic evaluation between jurisdictions
is limited. Further, because of the complexity of the decision-
making context, simple substitution of data inputs may not be
informative.
This is not, however, an argument against collaboration but
rather that the nature of collaboration is more sophisticated.
Several arguments can be presented in favor of using systematic
reviews of economic analyses to inform decision-making. These
same arguments can also apply when considering the value of an
economic evaluation conducted in one setting to inform decision-
making in another. In brief, existing evidence can be used to
inform the development of a new evaluation more relevant to the
jurisdiction of interest and the existing evidence can be used to
identify the key economic (causal) trade-offs implicit in a given
treatment choice. In terms of the adaptation scale discussed by
Simoens, the default is that transferring an economic evaluation
from one jurisdiction to another will require the sophisticated
adaptation (restructuring of the analytical framework, replace-
ment of data inputs, and potentially the introduction of new data
inputs required as a consequence of the restructuring of the
analytical framework) of an evaluation or the development of a
wholly new evaluation. It may be possible that less sophisticated
adaptation will be sufﬁcient in certain circumstances but until an
analyst is reasonably sure that differences in context requiring
more sophisticated work are unnecessary, the results of simpler
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analysis may be misleading and lead to a less efﬁcient use of
resources and potentially worse health for those people living in
the jurisdiction of interest.
Conclusion
This article has argued in favor of HTA and more speciﬁcally its
economic evaluation component being tailored to ﬁt national
circumstance. Many of the arguments presented here may also
apply to the other components of an HTA (e.g., the medical,
social, ethical implications of the development, diffusion and use
of a health technology). The economic aspect is not independent
of these other components and it is the differences in these
components and the way that they interact that require a
national perspective to be taken. There is, however, considerable
scope for collaboration between jurisdictions because lessons
from one jurisdiction can inform development or adaptation of
economic evaluations for another.
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